Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

633 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P. Juretzka MM, et al. Among authors: barakat rr. Gynecol Oncol. 2007 Jan;104(1):176-80. doi: 10.1016/j.ygyno.2006.07.027. Epub 2006 Sep 25. Gynecol Oncol. 2007. PMID: 16996584
Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems.
Zivanovic O, Leitao MM, Iasonos A, Jacks LM, Zhou Q, Abu-Rustum NR, Soslow RA, Juretzka MM, Chi DS, Barakat RR, Brennan MF, Hensley ML. Zivanovic O, et al. Among authors: barakat rr. J Clin Oncol. 2009 Apr 20;27(12):2066-72. doi: 10.1200/JCO.2008.19.8366. Epub 2009 Mar 2. J Clin Oncol. 2009. PMID: 19255317 Free PMC article.
Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses.
Fennelly D, Schneider J, Spriggs D, Bengala C, Hakes T, Reich L, Barakat R, Curtin J, Moore MA, Hoskins W, et al. Fennelly D, et al. Among authors: barakat r. J Clin Oncol. 1995 May;13(5):1160-6. doi: 10.1200/JCO.1995.13.5.1160. J Clin Oncol. 1995. PMID: 7537799 Clinical Trial.
Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer.
Aghajanian C, Fennelly D, Shapiro F, Waltzman R, Almadrones L, O'Flaherty C, O'Conner K, Venkatraman E, Barakat R, Curtin J, Brown C, Reich L, Wuest D, Norton L, Hoskins W, Spriggs DR. Aghajanian C, et al. Among authors: barakat r. J Clin Oncol. 1998 May;16(5):1852-60. doi: 10.1200/JCO.1998.16.5.1852. J Clin Oncol. 1998. PMID: 9586901 Clinical Trial.
633 results